XOMA Corp (NASDAQ:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation of data from XOMA 129, the lead compound in the Company’s XMetD antibody fragment (Fab) program, at the Endocrine Society’s Annual Meeting — ENDO 2016. A senior scientist at XOMA presented the Company’s poster titled “XOMA 129, a Novel Insulin Receptor Negative Modulator, is Efficacious in Treating Insulin- and Glibenclamide-induced Hypoglycemia in Animals.”
“Severe acute hypoglycemia is a common complication with diabetes therapies that requires prompt recognition and treatment to prevent severe toxicity and potentially mortality. XOMA 129, our novel Fab that binds to an allosteric site on the insulin receptor, was designed to have a rapid onset and limited duration of action, two important clinical requirements in reversing an acute hypoglycemic event,” stated Paul Rubin, M.D., Senior Vice President, Research and Development, and Chief Medical Officer at XOMA. “The data presented at ENDO 2016 demonstrate our Fab exhibits the rapidity of effect and clearance traits required, thereby leading us to believe XOMA 129 represents a novel potential treatment approach for these severe hypoglycemic episodes.”
The poster outlines XOMA 129’s performance in separate pre-clinical models: cell culture and animal pharmacology studies. In vitro assays showed XOMA 129 decreases the activity of insulin on mammalian cells over-expressing human, rat and minipig insulin receptor (INSR) in a dose-dependent manner. Further studies confirmed XOMA 129 binds to the INSR and acts as a negative allosteric modulator. In animal studies, potential rescue of insulin or sulphonylurea-induced hypoglycemia was modeled in normal rats. Administration of insulin or glibenclamide (a sulfonylurea) produced abnormally low glucose levels. Intravenous administration of XOMA 129 at time points wherein the drug-induced glucose levels were falling below normal levels rapidly stabilized blood glucose levels thereby preventing hypoglycemia. In normal minipigs, intramuscular administration yielded significant elevation of blood glucose lasting for several hours thereby confirming the activity in mammals. (Original Source)
Shares of Xoma closed last Friday at $0.785, up $0.01 or 1.55%. XOMA has a 1-year high of $4.93 and a 1-year low of $0.69. The stock’s 50-day moving average is $0.80 and its 200-day moving average is $1.07.
On the ratings front, Xoma has been the subject of a number of recent research reports. In a report issued on March 11, Wedbush analyst Liana Moussatos reiterated a Buy rating on XOMA, with a price target of $3, which implies an upside of 282.2% from current levels. Separately, on March 10, RBC’s Adnan Butt maintained a Hold rating on the stock and has a price target of $2.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Liana Moussatos and Adnan Butt have a total average return of 4.5% and -10.6% respectively. Moussatos has a success rate of 35.2% and is ranked #630 out of 3775 analysts, while Butt has a success rate of 41.7% and is ranked #3626.
XOMA Corp. discovers and develops innovative antibody-based therapeutics. It combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations.